Atika Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54M Sell
4,225
-5,400
-56% -$674K 6.78% 2
2025
Q4
$117M Buy
+9,625
New +$1.1M 12.36% 1
2024
Q3
Sell
-720
Closed -$6.68M 119
2024
Q2
$6.68M Buy
+720
New +$64.6K 0.65% 53
2021
Q2
Sell
-2,120
Closed -$28.8M 115
2021
Q1
$28.8M Sell
2,120
-271,880
-99% -$40.7M 2.5% 5
2020
Q4
$38.6M Sell
274,000
-256,000
-48% -$32.8M 3.02% 3
2020
Q3
$59.1M Buy
530,000
+390,000
+279% +$43.7M 4.84% 2
2020
Q2
$15.7M Sell
140,000
-215,000
-61% -$21.2M 2.03% 11
2020
Q1
$27.5M Buy
+355,000
New +$31.4M 5.27% 2
2019
Q4
Sell
-238,500
Closed -$20.6M 1
2019
Q3
$18.2M Sell
238,500
-6,500
-3% -$540K 3.83% 2
2019
Q2
$21.5M Buy
245,000
+145,000
+145% +$12.4M 4.22% 1
2019
Q1
$9.05M Sell
100,000
-230,000
-70% -$19.6M 1.84% 15
2018
Q4
$23.7M Buy
330,000
+80,000
+32% +$6.45M 6.97% 1
2018
Q3
$24M Buy
250,000
+50,000
+25% +$4.85M 4.3% 3
2018
Q2
$19M Buy
200,000
+85,000
+74% +$7.81M 3.66% 2
2018
Q1
$10.1M Buy
+115,000
New +$10.5M 3.46% 4
2017
Q4
Sell
-245,000
Closed -$21.2M 78
2017
Q3
$21.2M Buy
+245,000
New +$19.6M 6.09% 2
2017
Q2
Sell
-142,000
Closed -$9.84M 90
2017
Q1
$9.84M Buy
+142,000
New +$9.54M 4.82% 2
2016
Q4
Sell
-170,000
Closed -$11.3M 74
2016
Q3
$11.3M Buy
+170,000
New +$10.5M 4.6% 2

Other funds holding XBI

Atika Capital Management's XBI Position: Q1 2022 in Review

Atika Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 153,000 shares — an estimated $14.1M sold.

Atika Capital Management first reported a position in XBI in Q3 2021 and held it in 2 quarters. The position peaked at $17.1M in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Atika Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Atika Capital Management sold 153,000 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $14.1M.
  • Atika Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and held it in 2 quarters.
  • Atika Capital Management's State Street SPDR S&P Biotech ETF position peaked at $17.1M in Q4 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Atika Capital Management's 13F filing for Q1 2022, filed 13 May 2022.